Different types of botulinum toxin in humans

Movement Disorders

Volumn 19, Issue SUPPL. 8, 2004, Pages

  Eleopra, Roberto ^a   Tugnoli, Valeria ^a   Quatrale, Rocco ^a   Rosetto, Ornella ^b   Montecucco, Cesare ^b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Botulinum toxin type A; Botulinum toxin type B; Botulinum toxin type C; Botulinum toxin type F; Diffusion; Duration of action; Electromyography

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN E; BOTULINUM TOXIN F; CLOSTRIDIUM TOXIN; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DYSTONIA; FEMALE; HAND MUSCLE; HUMAN; HUMAN EXPERIMENT; IMMUNITY; MALE; MUSCLE ACTION POTENTIAL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; SEROTYPE; STATISTICAL SIGNIFICANCE; VOLUNTEER; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; ELECTROSTIMULATION; EVOKED MUSCLE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; TIME;

ADULT; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; ELECTRIC STIMULATION; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE, SKELETAL; TIME FACTORS;

EID: 3042852947     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20010     Document Type: Article

References (36)

1. Jankovic J, Hallett M. Therapy with botulinum toxin. New York: Marcel Dekker; 1994.
2. Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Q Rev Biophys 1994;28:423-472.
3. Montecucco C, Schiavo G. Tetanus and botulinum neurotoxins: isolation and assay. Methods Enzymol 1995;248:643-652.
4. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000;80:717-766.
5. Humeau Y, Doussau F, Grant NJ, et al. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000;82. 427-446.
6. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
7. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problem with available materials. Neurology 1996;46:26-29.
8. Brin M. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;6:S146-S165.
9. Zuber M, Sebald M, Bathien N, De Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-1718.
10. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-154.
11. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-1629.
12. Dressler D. Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 2002;43:26-29.
13. Ludlow CL, Hallett M, Rhew K, Cola R, Shinìizu T, Sakaguchi G, Bagley JA, Schulz GM, Yin SG, Koda J. Therapeutic use of type F botulinum toxin. N Engl J Med 1992;326:349-350.
14. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-483.
15. Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 1996;11:181-184.
16. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-483.
17. Mezaki T, Kaji R, Kohara N, Fujii H, Katayama M, Shimizu T, Kimura J, Brin MF. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 1995;45:506-508.
18. Chen R, Karp BI, Hallett M. Botulinum toxin type F for treatment of dystonia: long-term experience. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology 1998;51: 1494-1496.
19. Tsui JKC, Hayward M, Ming Mak EK, Schulzer M. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. Neurology 1995;45:2109-2110.
20. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49:701-707.
21. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53:1431-1438.
22. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-1446.
23. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997; 49:189-194.
24. Setler PE. Pharmacology of botulinum toxin type B. Eur J Neurol 2001;8:9-12.
25. Dressler D, Benecke R, Bigalke H. Botulinum toxin type B (NeuroBloc) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 2003;250:67-69.
26. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. Neurology 2003;60(Suppl. 1):A465-466.
27. Arezzo JC, Litwak MS, Caputo FA, et al. Spread of paralytic activity of NeuroBloc (botulinum toxin type B) and Botox (botulinum toxin type A) in juvenile monkeys: an electrophysiological model. Eur J Neurol 2000;7:18.
28. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B and F in mice. Toxicon 2001;39:1815-1820.
29. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-38.
30. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 1997;224:91-94.
31. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 1998;256:135-138.
32. Eleopra R, Tugnoli V, De Grandis D, et al. Botulinum toxin serotype C treatment in subjects affected by focal dystonia and resistant to botulinum toxin serotype A. Neurology 1998;50(Suppl. 4):A72.
33. Eleopra R, Tugnoli V, Quatrale R, Gastaldo E, Rossetto O, De Grandis D, Montecucco C. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting. Clin Neurophysiol 2002; 113:1258-1264.
34. Leist M, Fava E, Montecucco C, et al. Peroxynitrite and NO-donors induce neuronal apoptosis by eliciting autocrine excitotoxicity. Eur J Neurosci 1997;9:1488-1498.
35. De Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parents terminals. Proc Natl Acad Sci U S A 1999;96:3200-3205.
36. Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum A toxin in humans. Muscle Nerve 1994; 17:1385-1392.